-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s...
More »SEARCH RESULT
Generics vs Big pharma, reloaded -Shamnad Basheer
-The Hindu The proposal to extend the time limit for State-level drug regulatory approvals from four to 10 years could hit the generics market In a scathing letter to the Government of India, the Indian Pharmaceutical Alliance (IPA) took issue with what it considered to be a backdoor extension for data exclusivity norms in the country. It pointed to the recent government proposal to change the four-year time limit for State-level drug...
More »Jerome Oberreit, Secretary General of Medecins Sans Frontieres (MSF) or Doctors without Borders, interviewed by A Rangarajan
-The Hindu MSF Secretary General Jerome Oberreit on the increasing threat to affordable health care worldwide. Médecins Sans Frontières (MSF) or Doctors without Borders, the international humanitarian medical aid organisation that is active in 69 countries, serves populations affected by epidemics, armed conflicts, natural calamities and manmade disasters. MSF has relied heavily on generic drugs, much of which has been sourced from India, to deliver health care to some of the most...
More »A disaster in the making -A Rangarajan
-Frontline Medecins Sans Frontieres warns that the free or regional trade agreements that are being negotiated, which seek to strengthen current patent regimes, are a potential threat to the developing world’s access to life-saving drugs, which it sources mostly from India. WHEN NELSON MANDELA’S GOVERNMENT passed the Medicines and Related Substances Control Act in 1997 to make medicines more accessible to the poor, 39 Big pharmaceutical companies filed law suits in...
More »From plate to plough: A thought for food -Ashok Gulati & Smriti Verma
-The Indian Express New FDI policy in food products is unlikely to be a game-changer by itself. Government must clear up the policy environment. n a rather bold move on June 20, the Modi government opened several key sectors such as defence, pharmaceuticals, civil aviation and food products to 100 per cent foreign direct investment (FDI). The objective behind this FDI policy is to attract higher investments, better technologies in manufacturing, commerce,...
More »